Travere Therapeutics to Present at Upcoming Investor Conferences
27 mai 2021 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, May 27, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will present at the following upcoming virtual investor conferences in...
Travere Therapeutics Reports First Quarter 2021 Financial Results
06 mai 2021 16h01 HE
|
Travere Therapeutics, Inc.
Pivotal PROTECT Study of sparsentan in IgA nephropathy nears completion of patient enrollment; topline proteinuria data expected 3Q21 Net product sales of $47.4 million for the first quarter of...
Travere Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
01 mars 2021 16h01 HE
|
Travere Therapeutics, Inc.
Recently reported that ongoing DUPLEX Study of sparsentan in FSGS achieved interim proteinuria endpoint Preparations underway for meetings with regulatory agencies in first half of 2021 to discuss...
Travere Therapeutics Recognizes Rare Disease Day 2021 and the Importance of Working Together to Innovate and Address Healthcare Disparities in Rare Disease
25 févr. 2021 08h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) will join the National Organization for Rare Disorders (NORD), the European Organisation for Rare...
Travere Therapeutics Announces European Commission Has Granted Orphan Designation to Sparsentan for the Treatment of IgA Nephropathy
18 févr. 2021 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the European Commission (EC) has granted orphan designation to sparsentan for the treatment of...
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
17 févr. 2021 16h05 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the completion of its previously announced underwritten public offering of 7,532,500 shares of...